|1.||Nakajima, Atsushi: 4 articles (12/2008 - 03/2005)|
|2.||Wada, Koichiro: 4 articles (12/2008 - 03/2005)|
|3.||Takahashi, Hirokazu: 4 articles (12/2008 - 03/2005)|
|4.||Tomimoto, Ayako: 3 articles (12/2008 - 09/2006)|
|5.||Nakagama, Hitoshi: 3 articles (12/2008 - 09/2006)|
|6.||Endo, Hiroki: 2 articles (12/2008 - 10/2008)|
|7.||Saito, Satoru: 2 articles (12/2008 - 10/2008)|
|8.||Inamori, Masahiko: 2 articles (12/2008 - 10/2008)|
|9.||Yoneda, Masato: 2 articles (12/2008 - 09/2006)|
|10.||Sugiyama, Michiko: 2 articles (12/2008 - 10/2008)|
04/01/2006 - "Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia."
04/01/2006 - "Rats were pretreated with low-dose lipopolysaccharide (1 mg/kg intraperitoneally, 24 hrs before induction of endotoxemia) in the absence or presence of the selective PPAR-gamma antagonists GW9662 (1 mg/kg intraperitoneally) or T0070907 (1 mg/kg intraperitoneally) or the selective cyclooxygenase-2 inhibitor parecoxib (20 mg/kg intraperitoneally). "
|2.||Breast Neoplasms (Breast Cancer)
03/01/2011 - "This study examines whether selective antagonism of PPARγ with T0070907 is a potential strategy for breast cancer therapy. "
03/01/2011 - "The PPARgamma antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms."
01/01/2013 - "Treatment with 0.5-6 μM γ-tocotrienol, 0.4-50 μM PPARγ agonists (rosiglitazone or troglitazone), or 0.4-25 μM PPARγ antagonists (GW9662 or T0070907) alone resulted in a dose-responsive inhibition of MCF-7 and MDA-MB-231 breast cancer proliferation. "
|3.||Hepatocellular Carcinoma (Hepatoma)
11/01/2014 - "Three cervical cancer cell lines (HeLa, SiHa, and Me180) were treated with a PPARγ inhibitor, T0070907, and/or radiation. "
11/01/2014 - "T0070907, a PPAR γ inhibitor, induced G2/M arrest enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe."
08/01/2012 - "In addition, PPARγ activity inhibition by its antagonist T0070907 did not significantly reverse the enhanced effect of furanodiene and TAM suggesting that anti-cancer properties of combination were PPARγ independent. "
01/01/2014 - "Cell growth assay, Western blotting, Annexin V and flow cytometry analysis consistently showed that treatment with troglitazone (TGZ, a PPAR-γ agonist) led to dose-dependent inhibition of cervical cancer cell growth through apoptosis, whereas T0070907 (another PPAR-γ antagonist???) had no effect on Hela cell proliferation and apoptosis. "
03/15/2005 - "The PPARgamma inhibitor T0070907 was significantly more efficient at causing cancer cell death than the activators troglitazone and rosiglitazone. "
|5.||Wounds and Injuries (Trauma)
10/01/2008 - "Cell motility was examined by assaying transwell migration and wound filling in Capan-1 and Panc-1 pancreatic cancer cells, with or without the PPARgamma-specific inhibitor T0070907. "
06/01/2011 - "A controlled cortical impact (CCI) injury was induced in male C57BL/6 mice to investigate following endpoints: (1) mRNA expression of PPAR-γ and PPAR-γ target genes (LPL, GLT1, and IRAP/Lnpep), and inflammatory markers (TNF-α, IL-1β, IL-6, and iNOS), at 15 min, 3 h, 6 h, 12 h, and 24 h post-trauma; (2) contusion volume, neurological function, and gene expression after 24 h in mice treated with pioglitazone (0.5 and 1 mg/kg) or rosiglitazone (5 and 10 mg/kg IP at 30 min post-trauma); and (3) the role of PPAR-γ to mediate protection was determined in animals treated with pioglitazone, the PPAR-γ inhibitor T0070907, and a combination of both. "
|5.||Peroxisome Proliferator-Activated Receptors (PPAR)
|6.||Cyclooxygenase 2 (Cyclooxygenase-2)
|1.||Heterologous Transplantation (Xenotransplantation)